FDA Exempts COVID-19 Prescription Drugs From DSCSA Tracing Requirements
Executive Summary
Prescription drugs that are deemed necessary for treating patients in public health emergencies such as COVID-19 would not have to comply with DSCSA tracing requirements, says the FDA. Such drugs would not need to have product identifiers and saleable returns would not have to be verified.